Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Regeneron Pharmaceuticals 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 USA

www.regeneron.com P: 914-847-7000

Description:

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

Key Statistics

Overview:

Market Capitalization, $K 89,698,240
Enterprise Value, $K 88,573,744
Shares Outstanding, K 108,947
Annual Sales, $ 12,173 M
Annual Net Income, $ 4,338 M
Last Quarter Sales, $ 3,363 M
Last Quarter Net Income, $ 1,008 M
EBIT, $ 4,221 M
EBITDA, $ 4,562 M
60-Month Beta 0.14
% of Insider Shareholders 8.83%
% of Institutional Shareholders 84.15%
Float, K 99,327
% Float 91.17%
Short Volume Ratio 0.66

Growth:

1-Year Return 8.66%
3-Year Return 71.10%
5-Year Return 115.36%
5-Year Revenue Growth 107.30%
5-Year Earnings Growth 199.11%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 11.59 on 11/02/23
Next Earnings Date N/A
Earnings Per Share ttm 38.36
EPS Growth vs. Prev Qtr 15.70%
EPS Growth vs. Prev Year 1.90%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

REGN Ratios

Ratio
Price/Earnings ttm 21.24
Price/Earnings forward 22.92
Price/Earnings to Growth 3.07
Return-on-Equity % 18.61%
Return-on-Assets % 14.49%
Profit Margin % 35.64%
Net Margin % -33.60
Debt/Equity 0.11
Price/Sales 7.29
Price/Cash Flow 18.30
Price/Book 3.56
Book Value/Share 228.59
Interest Coverage 82.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar